Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 5 OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Transitional Cell 14 Urinary Bladder Neoplasms 11 Breast Neoplasms 11 Neoplasm Metastasis 10 Carcinoma, Renal Cell 8 Carcinoma, Merkel Cell 8 Neoplasms 7 Colorectal Neoplasms 7 Head and Neck Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Neuroendocrine Tumors 4 Leukemia, Myeloid, Acute 4 Urethral Neoplasms 3 Ureteral Neoplasms 3 Skin Neoplasms 3 Prostatic Neoplasms 3 Glioblastoma 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Neuroendocrine 3 Carcinoma, Hepatocellular 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Penile Neoplasms 2 Pancreatic Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 Neoplasm, Residual 2 Mesothelioma, Malignant 2

Interventions

Cyclophosphamide 115 Dexamethasone 70 fludarabine phosphate 57 Cytarabine 56 fludarabine 52 Rituximab 51 Peripheral Blood Stem Cell Transplantation 40 Etoposide 40 Gemcitabine 39 Lenalidomide 38 pembrolizumab 33 Radiotherapy 33 Busulfan 33 Filgrastim 32 Carboplatin 31 Methotrexate 30 Cyclosporine 29 Cisplatin 29 Bortezomib 29 Mycophenolic Acid 28 Melphalan 28 venetoclax 27 Paclitaxel 26 Whole-Body Irradiation 24 Antilymphocyte Serum 23 Temozolomide 22 Granulocyte Colony-Stimulating Factor 20 Calcium Dobesilate 20 Bevacizumab 20 Tacrolimus 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Recurrence × avelumab × Clear all

NCT04562441 2025-01-10

NPC - AXEL Study : Axitinib-Avelumab

Chinese University of Hong Kong

Phase 2 Completed

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡